The following sets forth the total stock-based compensation expense for employee equity plans included in the Company’s condensed consolidated statements of operations:


	Three Months Ended April 30,
	2023		2022
	(in thousands)
Cost of revenue	$	996	$	771
Research and development	9,506		5,803
Sales and marketing	4,169		2,324
General and administrative	9,293		6,629
Total stock-based compensation expense	$	23,964	$	15,527

As of April 30, 2023, the Company had unrecognized stock-based compensation expense related to stock options, RSUs and PRSUs (as defined below), and 2021 ESPP (as defined below) of $175.7 million, which is expected to be recognized over a weighted-average period of 2.64 years.

The 2021 Employee Stock Purchase Plan (“2021 ESPP”) permits participants to purchase shares of the Company’s Common Stock at a discounted price through payroll deductions. As of April 30, 2023, 13,842,252 shares of Common Stock were available under the 2021 ESPP.

The 2021 Equity Incentive Plan (“2021 EIP”) allows the Company to grant stock options, stock appreciation rights, restricted stock units (“RSUs”), performance restricted stock units (“PRSUs”), and certain other awards. As of April 30, 2023, 57,002,218 shares of Common Stock were available under the 2021 EIP.

A summary of RSUs outstanding under the 2021 EIP as of April 30, 2023 and changes during the period then ended is presented in the following table:


	Number of Shares	Weighted Average Grant Date Fair Value per Share
Outstanding as of January 31, 2023	12,935,413	$	15.02
RSU granted	661,578	$	11.08
RSU vested	(990,069)	$	16.42
RSU forfeited	(658,019)	$	15.19
Outstanding as of April 30, 2023	11,948,903	$	14.68

A summary of PRSUs outstanding under the 2021 EIP as of April 30, 2023 and changes during the fiscal year-to-date period then ended is presented in the following table:


	Number of Shares	Weighted Average Grant Date Fair Value per Share
Outstanding as of January 31, 2023	2,147,366	$	10.83
PRSUs granted	60,892	$	8.21

PRSU forfeited	(143,266)	$	10.47
Outstanding as of April 30, 2023	2,064,992	$	10.77

In fiscal year 2022, the Company terminated its 2017 Stock Option Plan (the “2017 Plan”) and 2007 Stock Option Plan (the “2007 Plan”).

A summary of options outstanding under the 2017 Plan and 2007 Plan as of April 30, 2023 and changes during the fiscal year-to-date period then ended is presented in the following table:


	Number of Stock Option Awards	Weighted Average Exercise Price		Weighted Average Remaining Contractual term (in years)	Aggregate Intrinsic Value (in thousands)
Outstanding as of January 31, 2023	17,600,524	$	0.70	5.6	$	201,352
Options exercised	(1,291,626)	$	0.71
Options cancelled	(90,094)	$	0.76

Outstanding as of April 30, 2023	16,218,804	$	0.70	5.6	$	129,283
Options vested and expected to vest as of April 30, 2023	16,182,144	$	0.70	5.6	$	128,993
Exercisable as of April 30, 2023	13,562,506	$	0.69	5.3	$	108,272